PubRank

Michael Ezekowitz

Author PubWeight™ 32.03‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012 4.33
2 Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009 3.18
3 Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation 2013 2.48
4 Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 2012 2.18
5 Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 2012 1.83
6 Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 2002 1.60
7 The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail 2004 1.54
8 Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace 2011 1.35
9 Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation 2014 1.30
10 Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol 2012 1.24
11 Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 1.20
12 Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace 2013 1.16
13 Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey. Clin Ther 2003 1.10
14 Diastolic dysfunction and atrial fibrillation. J Interv Card Electrophysiol 2008 0.98
15 Physicians' attitudes and the use of oral anticoagulants: surveying the present and envisioning future. J Thromb Thrombolysis 2004 0.96
16 Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study. J Am Coll Cardiol 2012 0.93
17 Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. Thromb Haemost 2011 0.87
18 Electrocardiographic Early Repolarization: A Scientific Statement From the American Heart Association. Circulation 2016 0.86
19 Advancement in antithrombotics for stroke prevention in atrial fibrillation. J Interv Card Electrophysiol 2008 0.83
20 Chronic antithrombotic therapy in post-myocardial infarction patients. Cardiol Clin 2008 0.78
21 Atrial fibrillation: modern concepts and management. Annu Rev Med 2005 0.75
22 Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”. Circulation 2013 0.75
23 Chronic antithrombotic therapy in post-myocardial infarction patients. Clin Geriatr Med 2006 0.75
24 Direct thrombin inhibitors: stroke prevention in atrial fibrillation and potential anti-inflammatory properties. Am Heart J 2005 0.75